The Road to Remission: Assessing Today's Treatment Goals in Crohn's Disease

CMEO Webcast

Premiere Date: Friday, October 30, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Saturday, October 30, 2021

Begin Activity Now

Faculty


Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP 
Professor and Chair
Department of Gastroenterology, Hepatology & Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic
Cleveland, OH

Marla C. Dubinsky, MD Marla C. Dubinsky, MD 
Professor, Department of Pediatrics
Chief, Pediatric Gastroenterology and Nutrition
Co-Director, The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Icahn School of Medicine at Mount Sinai
New York, NY

David T. Rubin, MD, FACG, AGAF, FACP, FASGE David T. Rubin, MD, FACG, AGAF, FACP, FASGE 
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Statement of Need

Crohn’s disease (CD), an inflammatory bowel disease (IBD) that affects at least 780,000 people in the United States, has recently seen its management goals evolve from merely controlling flares to achieving and sustaining deep remission, which can help a patient avoid progressive bowel wall damage. The only treatments effective in achieving durable deep remission are novel targeted therapies, which makes it imperative for clinicians to have a working knowledge of these treatments and to optimally incorporate them into their clinical practice.

This webcast will feature case-based learning supported by expert faculty translation, providing a real-world roadmap for the management of CD that reflects these changing treatment goals. Special attention will be paid to identifying predictors for treatment response, differentiating targeted therapies, and translating available efficacy data into real-world effectiveness so that clinicians will be able to choose the appropriate therapies at the right times for individual patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify predictors for treatment response and durable remission in patients with CD.
  • Differentiate appropriate targets of effective therapies in moderate-severe CD.
  • Translate available efficacy data into real-world effectiveness in order to choose the appropriate therapy for the right patient at the right time.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-105-H01-P

Type: Knowledge-based

ABIM MOC Credit:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format:
Enduring material

Royal College MOC Credit: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity, NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Dubinsky reports she receives grants from AbbVie Inc.; Pfizer Inc.; and Prometheus Laboratories Inc. She is a consultant for AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Merck & Co., Inc.; Projections Research Inc.; Prometheus Laboratories Inc.; and Rebiotix Inc.; and Takeda Pharmaceuticals U.S.A., Inc. She is a stock shareholder (directly purchased) in Trellus Health. She is the Co-Founder of MiTest Health, LLC.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Biomica; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation/ Syneos Health; Check-Cap; Dizal Pharmaceutical; Eli Lilly and Company; GalenPharma/Atlantica; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Ichnos Sciences SA; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Laboratories Inc.; Reistone Biopharma; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Techlab, Inc. He is a stock shareholder (directly purchased) in AbGenomics and Biomica. He receives other financial or material support as Co-Founder and CFO of Cornerstones Health, Inc.; and Co-Founder of GoDuRn, LLC. (non-profit).

Tony Graham, MD (peer review) has no disclosures to report.

Mae Ochoa, RPh MD (peer review) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMV-103-102920-01